Elevated F2-isoprostanes in thalassemic patients.

[1]  E. Vichinsky,et al.  Oxidative stress and inflammation in iron‐overloaded patients with β‐thalassaemia or sickle cell disease , 2006 .

[2]  B. Halliwell,et al.  Cautions in the use of biomarkers of oxidative damage; the vascular and antioxidant effects of dark soy sauce in humans. , 2006, Biochemical and biophysical research communications.

[3]  R. Naithani,et al.  Peroxidative stress and antioxidant enzymes in children with β‐thalassemia major , 2006 .

[4]  S. Gangemi,et al.  Increased protein carbonyl groups in the serum of patients affected by thalassemia major , 2006, Annals of Hematology.

[5]  J. Morrow.  Quantification of Isoprostanes as Indices of Oxidant Stress and the Risk of Atherosclerosis in Humans , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  E. Rachmilewitz,et al.  MEDICAL PROGRESS : β-thalassemia , 2005 .

[7]  P. Mecocci,et al.  Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. , 2004, Journal of cardiac failure.

[8]  B. Chung,et al.  Increased urinary F2-isoprostanes levels in the patients with Alzheimer’s disease , 2004, Brain Research Bulletin.

[9]  B. Halliwell,et al.  Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry. , 2004, Biochemical and biophysical research communications.

[10]  B. Halliwell,et al.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? , 2004, British journal of pharmacology.

[11]  I. Papassotiriou,et al.  A rare example that coinheritance of a severe form of β-thalassemia and α-thalassemia interact in a “synergistic” manner to balance the phenotype of classic thalassemic syndromes , 2004 .

[12]  G. FitzGerald,et al.  F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. , 2004, Chemistry and physics of lipids.

[13]  D. Tsikas,et al.  Urinary 8-iso-Prostaglandin F2&agr; as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study , 2004 .

[14]  S. Basu.  ReviewIsoprostanes: Novel Bioactive Products of Lipid Peroxidation , 2004, Free radical research.

[15]  T. Montine,et al.  Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  S. Laradi,et al.  Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[17]  M. Stacey,et al.  Iron and 8-isoprostane levels in acute and chronic wounds. , 2003, The Journal of investigative dermatology.

[18]  J. Morrow,et al.  The isoprostanes: unique products of arachidonic acid oxidation-a review. , 2003, Current medicinal chemistry.

[19]  A. Dash,et al.  A simple LC method with UV detection for the analysis of creatine and creatinine and its application to several creatine formulations. , 2002, Journal of pharmaceutical and biomedical analysis.

[20]  M. Cappellini,et al.  Oxidative status and malondialdehyde in β‐thalassaemia patients , 2002 .

[21]  B. Bonaz,et al.  Increased urinary F2-isoprostanes in patients with Crohn's disease. , 2002 .

[22]  K.,et al.  Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. , 2001, Kidney international.

[23]  F. Cuccurullo,et al.  Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. , 2001, Free radical biology & medicine.

[24]  M. Bhattacharyya,et al.  Antioxidant defense status of red blood cells of patients with β-thalassemia and Eβ-thalassemia , 2001 .

[25]  B. Halliwell.  Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? , 2000, Cardiovascular research.

[26]  B. Halliwell.  Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. , 2009, Nutrition reviews.

[27]  S. Basu,et al.  Metabolism of 8‐iso‐prostaglandin F2α , 1998 .

[28]  R. Hillman,et al.  Hematology in clinical practice : a guide to diagnosis and management , 1995 .

[29]  A. Dabbagh,et al.  The effect of iron overload on rat plasma and liver oxidant status in vivo. , 1994, The Biochemical journal.

[30]  A. Hoffbrand,et al.  Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1 , 1992, British journal of haematology.

[31]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Mccomb,et al.  Candidate reference method for determination of total bilirubin in serum: development and validation. , 1985, Clinical chemistry.

[33]  R. Carrell,et al.  The estimation of red cell superoxide dismutase activity. , 1975, The Journal of laboratory and clinical medicine.

[34]  J. Stocks,et al.  The Autoxidation of Human Red Cell Lipids Induced by Hydrogen Peroxide , 1971, British journal of haematology.

[35]  E. Beutler,et al.  Improved method for the determination of blood glutathione. , 1963, The Journal of laboratory and clinical medicine.